Related Experiment Video
Updated: Dec 12, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Feedback activation of GATA1/miR-885-5p/PLIN3 pathway decreases sunitinib sensitivity in clear cell renal cell
Dayong Yao1, Shunyao Xia1, Chengjun Jin1
1Department of Urology, The First Affiliated Hospital of Harbin Medical University , Harbin, China.
Abstract:
Sunitinib is the most commonly used first-line therapy for the treatment of advanced renal cell carcinoma (RCC), but intrinsic and extrinsic resistance to targeted therapies dramatically compromise the benefit of clinical outcome. Dissecting the underlying mechanisms and discovering reliable predictive biomarkers are urgently needed in clinic. Here, we discovered miR-885-5p was notably decreased after sunitinib treatment and associated with poor disease progression in clear cell renal cell carcinoma (ccRCC). In vitro and in vivo studies identified miR-885-5p inhibition contributed to sunitinib resistance. Mechanistically, sunitinib treatment reduced GATA1 expression, which in turn reduced its binding to MIR885 promoter and resulted in miR-885-5p downregulation in transcriptional level. In addition, PLIN3 was confirmed to be directly targeted by miR-885-5p and its upregulation significantly increased lipid droplets formation to decrease sunitinib sensitivity. Therefore, GATA1/miR-885-5p/ PLIN3 pathway may serve as a potential therapeutic strategy and a biomarker for sunitinib treatment in ccRCC.
Insights
A new study reveals that decreased miR-885-5p levels correlate with poor outcomes in advanced renal cell carcinoma (RCC) patients treated with sunitinib, suggesting a novel therapeutic target for overcoming drug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Sunitinib is a primary treatment for advanced renal cell carcinoma (RCC).
- Drug resistance significantly limits sunitinib's clinical effectiveness.
- Identifying resistance mechanisms and biomarkers is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the role of miR-885-5p in sunitinib resistance in clear cell renal cell carcinoma (ccRCC).
- To elucidate the molecular mechanisms underlying miR-885-5p dysregulation and its impact on sunitinib sensitivity.
Main Methods:
- Analysis of miR-885-5p expression in ccRCC patients treated with sunitinib.
- In vitro and in vivo studies to assess the functional role of miR-885-5p.
- Investigation of the GATA1/miR-885-5p/PLIN3 regulatory pathway.
Main Results:
- miR-885-5p was downregulated in ccRCC patients with poor response to sunitinib.
- Reduced miR-885-5p expression contributed to sunitinib resistance.
- Sunitinib treatment decreased GATA1, leading to reduced miR-885-5p transcription.
- miR-885-5p targets PLIN3, and its upregulation promotes lipid droplet formation, decreasing sunitinib sensitivity.
Conclusions:
- The GATA1/miR-885-5p/PLIN3 pathway is implicated in sunitinib resistance in ccRCC.
- miR-885-5p may serve as a predictive biomarker for sunitinib treatment.
- Targeting this pathway offers a potential therapeutic strategy for overcoming sunitinib resistance in ccRCC.
More Related Videos
Related Concept Videos
TGF - β Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

